CLAIMS

What is claimed is:

1. Use of riluzole, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a disease in a patient in need thereof, wherein the medicament is in the form of an oral solid molded fast-dispersing dosage form in order to provide an $AUC_{0-t}$ of from about 80-125% of about 740000 hr*pg/mL, wherein the dosage of riluzole in the oral solid molded fast dispersing tablet is from 50 to 90% of the dosage of riluzole in a conventional tablet in order to provide an $AUC_{0-t}$. of about 740000 hr*pg/mL.

2. The use of claim 1 wherein the dosage of riluzole in the oral solid molded fast dispersing tablet is from 70 to 85% of the dosage of riluzole in a conventional tablet in order to provide an $AUC_{0-t}$. of about 740000 hr*pg/mL

3. The use of claim 2 wherein the dosage of riluzole in the oral solid molded fast dispersing tablet is about 80% of the dosage of riluzole in a conventional tablet in order to provide an $AUC_{0-t}$. of about 740000 hr*pg/mL.

4. The use of claim 1 wherein the dosage of riluzole in the oral solid molded fast dispersing tablet is about 40mg.

5. The use of claim 1 wherein the disease is ALS.

6. A pharmaceutical composition comprising a therapeutically effective amount of riluzole, or a pharmaceutically acceptable salt thereof, in the form of an oral solid molded fast-dispersing dosage form in order to provide an $AUC_{0-t}$ of from about 80-125% of about 740000 hr*pg/mL, wherein the dosage of riluzole in the oral solid molded fast dispersing tablet is from 50 to 90%, more preferably 70 to 85% and most preferably about 80% o of the dosage of riluzole in a conventional tablet in order to provide an $AUC_{0-t}$. of about 740000 hr*pg/mL.

7. The pharmaceutical composition of claim 6 wherein the dosage of riluzole in the oral solid molded fast dispersing tablet is from 70 to 85% of the dosage of riluzole in a conventional tablet in order to provide an $AUC_{0-t}$. of about 740000 hr*pg/mL.

8. The pharmaceutical composition of claim 6 wherein the dosage of riluzole in the oral solid molded fast dispersing tablet is about 80% of the dosage of riluzole in a conventional tablet in order to provide an $AUC_{0-t}$. of about 740000 hr*pg/mL.

9. The pharmaceutical composition of claim 6 wherein the dosage of riluzole in the oral solid molded fast dispersing tablet is about 40 mg.

10. The pharmaceutical composition of claim 6 comprising from about 50-70 wt% riluzole, about 10-30 wt% fish gelatin, about 10-20 wt% of a filler, and 0.1-5.0 wt% of a flavorant.

11. The pharmaceutical composition of claim 10 wherein the filler is mannitol.

12. A kit for treating a disease in a patient, the kit comprising:

(a) a pharmaceutical composition comprising a therapeutically effective amount of riluzole, or a pharmaceutically acceptable salt thereof in the oral solid molded fast dispersing tablet;

(b) instructions for administering the pharmaceutical composition; wherein the therapeutically effective amount provides an $AUC_{0-t}$ of from about 80-125% of 740000 (hr*pg/mL).